Okuma Hitomi Sumiyoshi, Kobayashi Yukio, Makita Shinichi, Kitahara Hideaki, Fukuhara Suguru, Munakata Wataru, Suzuki Tatsuya, Maruyama Dai, Tobinai Kensei
Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan; Department of Medical Oncology, Graduate School of Medicine, Chiba University Hospital, Chiba, Chiba 260-8670, Japan.
Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Oncol Lett. 2016 Aug;12(2):809-814. doi: 10.3892/ol.2016.4683. Epub 2016 Jun 7.
Visceral disseminated varicella zoster virus (VZV) disease has a high mortality rate, and occurs in immunocompromised hosts, mostly subsequent to allogeneic stem cell transplantation. Only a few cases of this disease that onset during conventional chemotherapy in patients with lymphoma have been reported. The present study reports the cases of 3 patients with disseminated and visceral VZV infection undergoing treatment for follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. All 3 patients presented with initial symptoms of abdominal pain, and 2 patients demonstrated syndrome of inappropriate antidiuretic hormone and hepatitis. All patients developed widespread cutaneous dissemination, and all had a low cluster of differentiation 4 cell count or lymphocyte count at the time of VZV diagnosis and at least 4 month prior. With intravenous systemic acyclovir therapy (Cases 1 and 3, 1500 mg/day; Case 2, 750 mg/day), the patients achieved complete recovery by day 14 of therapy. Visceral disseminated VZV infection is not limited to patients undergoing stem cell transplantation, and may present with abdominal pain with or without skin eruption. Visceral infection may take a poor clinical course, therefore, in patients with prolonged duration of low lymphocyte count and/or long-term use of steroids, the prophylactic use of acyclovir may be considered.
内脏播散性水痘带状疱疹病毒(VZV)疾病死亡率高,发生于免疫功能低下宿主,大多在异基因干细胞移植后出现。仅有少数淋巴瘤患者在接受传统化疗期间发生该病的病例报道。本研究报告了3例分别患有滤泡性淋巴瘤、弥漫性大B细胞淋巴瘤和外周T细胞淋巴瘤(未另行分类)且正在接受治疗的播散性和内脏VZV感染患者的病例。所有3例患者最初均表现为腹痛症状,2例患者出现抗利尿激素分泌异常综合征和肝炎。所有患者均出现广泛的皮肤播散,且在VZV诊断时及至少4个月前,所有患者的CD4细胞计数或淋巴细胞计数均较低。通过静脉全身给予阿昔洛韦治疗(病例1和3,1500mg/天;病例2,750mg/天),患者在治疗第14天时实现完全康复。内脏播散性VZV感染并不局限于接受干细胞移植的患者,可能表现为有或无皮疹的腹痛。内脏感染可能临床病程不佳,因此,对于淋巴细胞计数持续低下和/或长期使用类固醇的患者,可考虑预防性使用阿昔洛韦。